This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pachón-Ibáñez, M. E.
Right arrow Articles by Pachón, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pachón-Ibáñez, M. E.
Right arrow Articles by Pachón, J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2004, p. 4479-4481, Vol. 48, No. 11
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.11.4479-4481.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Activity of Tigecycline (GAR-936) against Acinetobacter baumannii Strains, Including Those Resistant to Imipenem

María Eugenia Pachón-Ibáñez,1* Manuel Enrique Jiménez-Mejías,1 Cristina Pichardo,1 Ana Cristina Llanos,2 and Jerónimo Pachón1

Infectious Diseases Service,1 Microbiology Service, Virgen del Rocío University Hospitals, Seville, Spain2

Received 9 May 2004/ Returned for modification 9 June 2004/ Accepted 1 August 2004


arrow
ABSTRACT
 
We determined the in vitro activities of tigecycline and imipenem against 49 isolates of Acinetobacter baumannii, including those resistant to imipenem. The MIC at which 50% of the isolates were inhibited (MIC50) and the MIC90 for tigecycline and imipenem were 2 and 2 mg/liter and 32 and 128 mg/liter, respectively, with 92 and 20%, respectively, of the strains being susceptible. Tigecycline did not show bactericidal activity in the time-kill studies (n = 9 strains). Imipenem showed bactericidal activity against seven out of nine strains. These in vitro results show that tigecycline has good in vitro bacteriostatic activity against A. baumannii, including strains resistant to imipenem.


arrow
TEXT
 
Acinetobacter baumannii is a nonfermentative gram-negative rod that causes nosocomial infections, especially in intensive care units (4, 5, 11, 13), with increasing frequency. This organism usually affects immunocompromised, ventilator-dependent, or debilitated patients, causing a great number of clinical conditions, including pneumonia, bacteremia, urinary tract infections, wound infections, endocarditis, and meningitis (1, 4). The mortality of nosocomial infections by A. baumannii is high, reaching 25 to 34% for bacteremia and 40 to 80% (6, 8) for nosocomial pneumonia.

Management of A. baumannii infections can be complicated due to the emergence of isolates with multiple-drug resistance (4, 6), including resistance to carbapenems (3). Therefore, it is necessary to evaluate new molecules that are potentially useful against A. baumannii.

Tigecycline, a derivate of minocycline, is a glycylcycline that exhibits potent activity against a broad spectrum of bacteria (7, 10, 12, 13, 15, 18, 20), including Acinetobacter spp. (2, 7, 9). In this study, we determined the in vitro activity of tigecycline against nosocomial A. baumannii, including strains resistant to imipenem.

A. baumannii clinical isolates were identified with MicroScan (Baxter H.C., West Sacramento, Calif.), the API 20NE system (Bio-Mérieux, Marcy l'Etoile, France), and the temperature growth test (44°C). The strains were stored frozen at –80°C in brucella broth containing 20% glycerol until they were tested for susceptibility. Forty-nine strains from blood cultures corresponding to bacteremic patients were studied. Previously, these isolates were characterized molecularly by means of a repetitive extragenic palindromic sequence-based PCR method (14). The isolates were predominantly from the two quantitatively most important A. baumannii genotypes found in our institution (clones I and II).

For the determination of the MIC a broth microdilution method was used (cation-adjusted Mueller-Hinton broth; Becton Dickinson, Cockeysville, Md.), in accordance with the NCCLS guidelines (16). Imipenem (Merck Sharp & Dohme Madrid, Spain) and tigecycline (Wyeth-Ayerst, Pearl River, N.Y.) were the drugs tested. MICs were interpreted according to NCCLS criteria for non-Enterobacteriaceae (16). Because there is no approved standard for considering A. baumannii susceptible or resistant to tigecycline, provisional MIC breakpoints used for this agent were ≤2, 4, and ≥8 µg/ml to designate susceptible, intermediate, and resistant strains, respectively (Wyeth Research, personal communication). Escherichia coli ATCC 25922 and Staphylococcus aureus ATCC 29213 were used as quality control strains. The minimum bactericidal concentration (MBC) was defined as the lowest concentration of drug that resulted in the killing of 99.9% of the original inoculum (16, 19).

Nine isolates with different susceptibilities to imipenem were chosen for time-kill studies: three imipenem-susceptible strains (MIC = 1 µg/ml), three with intermediate susceptibility to imipenem (MIC = 8 µg/ml for one strain and MIC = 16 µg/ml for two strains), and three resistant to imipenem (MIC = 32 µg/ml). Organisms were grown on Mueller-Hinton broth for 4 h (log phase of growth) and were further diluted in 20 ml of the same medium to yield a concentration of approximately 5 x 105 CFU/ml, as verified by plate counts. Tigecycline powder was dissolved and prepared for in vitro testing according to instructions from the manufacturer and in compliance with NCCLS guidelines (16). Probe tubes contained imipenem or tigecycline at concentrations corresponding to the MIC and two and four times the MIC for each strain. Additional control tubes were inoculated with bacteria of each strain and without drugs. Tubes were incubated aerobically at 36°C for 24 h. Aliquots (0.1 ml of broth) were removed from each tube, and serial dilutions were plated onto blood-agar plates after 0, 2, 4, 8, and 24 h of incubation. Colony counts were performed after 24 h of incubation at 36°C. Bactericidal activity was defined as a ≥3 log10 reduction compared with the initial inoculum (16, 19).

Results of susceptibility tests (MIC and MBC) for imipenem and tigecycline are shown in Table 1. Thirty-eight isolates were imipenem resistant (78%), 1 isolate showed intermediate susceptibility to imipenem (2%), and 10 isolates were imipenem susceptible (20%). Conversely, 45 strains were tigecycline susceptible (92%), with a MIC range of 1 to 4 mg/liter.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Susceptibilities of 49 A. baumannii strains to imipenem and tigecycline

In time-kill studies, imipenem showed bactericidal activity against 3, 7, and 6 strains at the MIC, twice the MIC, and four times the MIC, respectively, beginning after 8 h of incubation (Table 2). On the other hand, tigecycline was not bactericidal against any strain at any tested concentration; it produced decreases of 2.99 and 2.84 log10 CFU/ml for one imipenem-intermediate strain and one imipenem-resistant strain, respectively.


View this table:
[in this window]
[in a new window]
  		TABLE 2. Time-kill results of imipenem against nine A. baumannii strains with different susceptibilities to imipenem

Our results show that 92% of the A. baumannii strains were tigecycline susceptible, by the provisional breakpoints previously detailed. Other in vitro studies have indicated that tigecycline is active against A. baumannii (2, 7, 9). One study (9) using the same provisional breakpoints for tigecycline showed that 91% of A. baumannii complex strains (n = 443 strains) were susceptible; however, only 2% of the strains included in this study had diminished susceptibility to imipenem (intermediate or resistant).

The MIC at which 90% of the isolates were inhibited (MIC90) of tigecycline in the present study was 2 µg/ml, equal to that found in other studies from the United Kingdom and the United States (9, 10) and lower than the MIC90 of 8 µg/ml found in the work by Betriu et al. from Spain (2). These results are valuable, taking into account that 78% of the strains in our study were imipenem resistant, with a MIC90 of imipenem of 128 µg/ml. In contrast, two other studies on the activity of tigecycline against A. baumannii found that only 28 and 0.4% of the strains were resistant to imipenem, with MIC90s of 128 and 0.5 µg/ml, respectively (2, 9).

Although tigecycline, like other derivatives of tetracycline, demonstrates bacteriostatic activity, it has been found to be bactericidal for a wide spectrum of gram-positive and gram-negative aerobic and anaerobic bacteria (18). Other studies have not included an evaluation of the bactericidal activity of tigecycline against A. baumannii (10, 12, 15, 17, 18). In the present study, tigecycline was not bactericidal against any strains, although for two of them the decrease in the count at 24 h was near 3 log10 CFU/ml.

In summary, tigecycline is active against A. baumannii strains, including those resistant to imipenem. The results of the time-kill studies show that tigecycline is bacteriostatic against A. baumannii.


arrow
ACKNOWLEDGMENTS
 
This study was supported by a research grant from Wyeth-Ayerst Research, Pearl River, N.Y.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Servicio de Enfermedades Infecciosas, Hospitales Universitarios Virgen del Rocío, Avda. Manuel Siurot s/n, 41013 Seville, Spain. Phone: 34 955012376. Fax: 34 955012377. E-mail: menia{at}telefonica.net. Back


arrow
REFERENCES
 
    1
  1. Bergogne-Bérézin, E., and K. J. Towner. 1996. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin. Microbiol. Rev. 9:148-165.[Medline]
    2. 2
  2. Betriu, C., I. Rodríguez-Avial, B. A. Sánchez, M. Gómez, J. Álvarez, J. J. Picazo, and the Spanish Group of Tigecycline. 2002. In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain. Antimicrob. Agents Chemother. 46:892-895.[Abstract/Free Full Text]
    3. 3
  3. Bou, G., G. Cerveró, M. A. Domínguez, C. Quereda, and J. Martínez-Beltrán. 2000. Characterization of nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A. baumannii is not due solely to the presence of ß-lactamases. J. Clin. Microbiol. 38:3299-3305.[Abstract/Free Full Text]
    4. 4
  4. Cisneros, J. M., M. J. Reyes, J. Pachón, B. Becerril, F. J. Caballero, J. L. García-Garmendia, C. Ortiz, and A. R. Cobacho. 1996. Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin. Infect. Dis. 22:1026-1032.[Medline]
    5. 5
  5. Corbellá, X., M. Pujor, J. Ayats, M. Sendra, C. Ardanuy, M. A. Domínguez, J. Liñares, J. Ariza, and F. Gudiol. 1996. Relevance of digestive tract colonization in the epidemiology of nosocomial infections due to multiresistant Acinetobacter baumannii. Clin. Infect. Dis. 23:329-334.[Medline]
    6. 6
  6. Fagon, J. Y., J. Chastre, A. J. Hance, et al. 1993. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am. J. Med. 94:281-288.[CrossRef][Medline]
    7. 7
  7. Gales, A. C., and R. N. Jones. 2000. Antimicrobial activity and spectrum of the new glycylcycline GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn. Microbiol. Infect. Dis. 36:19-36.[CrossRef][Medline]
    8. 8
  8. Garnacho-Montero, J., C. Ortiz-Leyba, F. J. Jiménez-Jiménez, A. E. Barrero-Almodóvar, J. L. García-Garmendia, M. Bernabeu-Wittel, S. L. Gallego-Lara, and J. Madrazo-Osuna. 2003. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin. Infect. Dis. 36:1111-1118.[CrossRef][Medline]
    9. 9
  9. Henwood, C. J., T. Gatward, M. Warner, D. James, M. W. Stockdale, R. P. Spence, K. J. Towner, D. M. Livermore, and N. Woodford. 2002. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J. Antimicrob. Chemother. 49:479-487.[Abstract/Free Full Text]
    10. 10
  10. Hoellman, D. B., G. A. Pankuch, M. R. Jacobs, and P. C. Appelbaum. 2000. Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci. Antimicrob. Agents Chemother. 44:1085-1088.[Abstract/Free Full Text]
    11. 11
  11. Horrevorts, A., K. Bergman, L. Kollee, I. Breuker, I. Tjernberg, and L. Dijkshoorn. 1995. Clinical and epidemiological investigations of Acinetobacter genomospecies 3 in a neonatal intensive care unit. J. Clin. Microbiol. 33:1567-1572.[Abstract]
    12. 12
  12. Jacobus, N. V., L. A. McDermott, R. Ruthazer, and D. R. Snydman. 2004. In vitro activities of tigecycline against the Bacteroides fragilis group. Antimicrob. Agents Chemother. 48:1034-1036.[Abstract/Free Full Text]
    13. 13
  13. Lortholary, O., J. Y. Fagon, A. B. Hoi, M. A. Slama, J. Pierre, P. Giral, R. Rosenzweig, L. Gutmann, M. Safar, and J. Acar. 1995. Nosocomial acquisition of Acinetobacter baumannii: risk factors and prognosis. Clin. Infect. Dis. 20:790-796.[Medline]
    14. 14
  14. Martín-Lozano, D., J. Cisneros, B. Becerril, L. Cuberos, T. Prados, C. Ortíz-Leyba, E. Cañas, and J. Pachón. 2002. Comparison of a repetitive extragenic palindromic sequence-based PCR method and clinical and microbiological methods for determining strain sources in cases of nosocomial Acinetobacter baumannii bacteremia. J. Clin. Microbiol. 40:4571-4575.[Abstract/Free Full Text]
    15. 15
  15. Murphy, T. M., J. M. Deitz, P. J. Petersen, S. M. Mikkels, and W. J. Weiss. 2000. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis. Antimicrob. Agents Chemother. 44:3022-3027.[Abstract/Free Full Text]
    16. 16
  16. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. M7-A6, 6th ed. National Committee for Clinical Laboratory Standards, Wayne, Pa.
    17. 17
  17. Petersen, P. J., P. A. Bradford, W. J. Weiss, T. M. Murphy, P. E. Sum, and S. J. Prodan. 2002. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens. Antimicrob. Agents Chemother. 46:2595-2601.[Abstract/Free Full Text]
    18. 18
  18. Petersen, P. J., N. V. Jacobus, W. J. Weiss, P. E. Sum, and R. Testa. 1999. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. 43:738-744.[Abstract/Free Full Text]
    19. 19
  19. Swenson, J. M., J. Hindler, and L. Peterson. 1999. Special phenotypic methods for detecting antibacterial resistance, p. 1563-1577. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology. ASM Press, Washington, D.C.
    20. 20
  20. Testa, R., P. J. Petersen, N. V. Jacobus, P. E. Sum, V. J. Lee, and F. P. Tally. 1993. In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines. Antimicrob. Agents Chemother. 37:2270-2277.[Abstract/Free Full Text]

Antimicrobial Agents and Chemotherapy, November 2004, p. 4479-4481, Vol. 48, No. 11
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.11.4479-4481.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Vasilev, K., Reshedko, G., Orasan, R., Sanchez, M., Teras, J., Babinchak, T., Dukart, G., Cooper, A., Dartois, N., Gandjini, H., Orrico, R., Ellis-Grosse, E., on behalf of the 309 Study Group, (2008). A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother 62: i29-i40 [Abstract] [Full Text]  
  • Valentine, S. C., Contreras, D., Tan, S., Real, L. J., Chu, S., Xu, H. H. (2008). Phenotypic and Molecular Characterization of Acinetobacter baumannii Clinical Isolates from Nosocomial Outbreaks in Los Angeles County, California. J. Clin. Microbiol. 46: 2499-2507 [Abstract] [Full Text]  
  • Peleg, A. Y., Seifert, H., Paterson, D. L. (2008). Acinetobacter baumannii: Emergence of a Successful Pathogen. Clin. Microbiol. Rev. 21: 538-582 [Abstract] [Full Text]  
  • Karageorgopoulos, D. E., Kelesidis, T., Kelesidis, I., Falagas, M. E. (2008). Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 62: 45-55 [Abstract] [Full Text]  
  • Song, J. Y., Kee, S. Y., Hwang, I. S., Seo, Y. B., Jeong, H. W., Kim, W. J., Cheong, H. J. (2007). In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 60: 317-322 [Abstract] [Full Text]  
  • Thamlikitkul, V., Tiengrim, S., Tribuddharat, C. (2007). Comment on: High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 60: 177-178 [Full Text]  
  • Brown, S. D., Traczewski, M. M. (2007). Comparative In Vitro Antimicrobial Activity of Tigecycline, a New Glycylcycline Compound, in Freshly Prepared Medium and Quality Control. J. Clin. Microbiol. 45: 2173-2179 [Abstract] [Full Text]  
  • Scheetz, M. H., Qi, C., Warren, J. R., Postelnick, M. J., Zembower, T., Obias, A., Noskin, G. A. (2007). In Vitro Activities of Various Antimicrobials Alone and in Combination with Tigecycline against Carbapenem-Intermediate or -Resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51: 1621-1626 [Abstract] [Full Text]  
  • Iredell, J., Thomas, L., Power, D., Mendes, E. (2007). Tigecycline resistance in Australian antibiotic-resistant Gram-negative bacteria. J Antimicrob Chemother 59: 816-818 [Full Text]  
  • Insa, R., Cercenado, E., Goyanes, M. J., Morente, A., Bouza, E. (2007). In vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophilia. J Antimicrob Chemother 59: 583-585 [Full Text]  
  • Kwon, K. T., Oh, W. S., Song, J.-H., Chang, H.-H., Jung, S.-I., Kim, S.-W., Ryu, S. Y., Heo, S. T., Jung, D. S., Rhee, J.-Y., Shin, S. Y., Ko, K. S., Peck, K. R., Lee, N. Y. (2007). Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrob Chemother 59: 525-530 [Abstract] [Full Text]  
  • Jones, R. N., Ferraro, M. J., Reller, L. B., Schreckenberger, P. C., Swenson, J. M., Sader, H. S. (2007). Multicenter Studies of Tigecycline Disk Diffusion Susceptibility Results for Acinetobacter spp.. J. Clin. Microbiol. 45: 227-230 [Abstract] [Full Text]  
  • Seifert, H., Stefanik, D., Wisplinghoff, H. (2006). Comparative in vitro activities of tigecycline and 11 other antimicrobial agents against 215 epidemiologically defined multidrug-resistant Acinetobacter baumannii isolates. J Antimicrob Chemother 58: 1099-1100 [Full Text]  
  • Lolans, K., Rice, T. W., Munoz-Price, L. S., Quinn, J. P. (2006). Multicity Outbreak of Carbapenem-Resistant Acinetobacter baumannii Isolates Producing the Carbapenemase OXA-40.. Antimicrob. Agents Chemother. 50: 2941-2945 [Abstract] [Full Text]  
  • Scheetz, M. H., Hurt, K. M., Noskin, G. A., Oliphant, C. M. (2006). Applying antimicrobial pharmacodynamics to resistant gram-negative pathogens.. Am J Health Syst Pharm 63: 1346-1360 [Abstract] [Full Text]  
  • Kasbekar, N. (2006). Tigecycline: A new glycylcycline antimicrobial agent.. Am J Health Syst Pharm 63: 1235-1243 [Abstract] [Full Text]  
  • Livermore, D. M. (2005). Tigecycline: what is it, and where should it be used?. J Antimicrob Chemother 56: 611-614 [Abstract] [Full Text]  
  • Pankey, G. A. (2005). Tigecycline. J Antimicrob Chemother 56: 470-480 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pachón-Ibáñez, M. E.
Right arrow Articles by Pachón, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pachón-Ibáñez, M. E.
Right arrow Articles by Pachón, J.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»